Weekly Endocrinology Research Analysis
This week’s endocrinology literature highlights three high-impact, translational studies: a proteome-wide MR plus clinical validation nominating plasma CXCL10 as a discriminative biomarker for LADA; a mechanistic Hepatology paper identifying hepatocyte exosomal NAT10 as a targetable driver of MASH fibrosis with effective GalNAc‑siRNA intervention in models; and an integrated multi-omics study defining a CHSY1/GAG-driven metabolic poor‑prognosis subtype in medullary thyroid cancer. Together these
Summary
This week’s endocrinology literature highlights three high-impact, translational studies: a proteome-wide MR plus clinical validation nominating plasma CXCL10 as a discriminative biomarker for LADA; a mechanistic Hepatology paper identifying hepatocyte exosomal NAT10 as a targetable driver of MASH fibrosis with effective GalNAc‑siRNA intervention in models; and an integrated multi-omics study defining a CHSY1/GAG-driven metabolic poor‑prognosis subtype in medullary thyroid cancer. Together these studies advance diagnostic biomarkers, nominate novel therapeutic targets, and demonstrate multi‑platform approaches that could change clinical risk stratification and therapeutic development.
Selected Articles
1. Integrative proteogenomic and observational analysis identifies potential biomarkers for latent autoimmune diabetes in adults.
Proteome-wide Mendelian randomization with cis‑pQTLs identified elevated genetically predicted CXCL10 (and SAA1/SAA2) as associated with increased LADA risk; CXCL10 showed the most robust causal evidence and, in an independent clinical cohort (n=241), discriminated LADA from T2D and controls with ROC‑AUC 0.838–0.889 and good calibration. Phenome-wide MR suggested no major safety liabilities for CXCL10 as a biomarker/target.
Impact: Combines causal proteogenomic inference and independent clinical validation to nominate a translatable blood biomarker (CXCL10) that can reduce LADA–T2D diagnostic ambiguity and inform earlier, appropriate therapy.
Clinical Implications: CXCL10 measurement could improve early recognition of LADA and guide immunologic/insulin‑focused management; prospective, multi‑ancestry validation and cutoff calibration are required prior to routine clinical use.
Key Findings
- Proteome‑wide MR and colocalization linked genetically higher plasma CXCL10, SAA1, and SAA2 to increased LADA risk.
- CXCL10 had strongest multi-layer support and discriminated LADA from T2D/controls in a matched clinical cohort (ROC‑AUC 0.838–0.889).
- Phenome‑wide MR across 1,006 traits did not reveal major safety concerns for CXCL10 as a target/biomarker.
2. Palmitoylation-mediated exosomal trafficking of nuclear protein NAT10 potentiates liver fibrosis in MASH.
Proteomic and mechanistic studies identify hepatocyte‑derived exosomal NAT10 as enriched under lipotoxic stress; ZDHHC23‑mediated palmitoylation drives NAT10 nuclear export and exosomal loading, and exosomal NAT10 stabilizes Ddr2 mRNA via ac4C RNA acetylation to activate stellate cells. Hepatocyte‑specific Nat10 deletion or GalNAc‑siNat10 therapy markedly reduced fibrosis in murine MASH models, with human liver correlates linking NAT10 mislocalization to fibrosis severity.
Impact: Uncovers a novel, targetable exosome‑mediated fibrogenic axis linking nuclear protein trafficking, RNA acetylation, and stellate cell activation; provides preclinical therapeutic proof‑of‑concept with hepatocyte‑targeted siRNA.
Clinical Implications: Although preclinical, NAT10 (or its palmitoylation/ZDHHC23 machinery) is a promising antifibrotic target for MASH; translation will require selective inhibitors or optimized hepatocyte delivery of siRNA and safety evaluation of modulating RNA acetylation.
Key Findings
- Hepatocyte exosomal NAT10 is enriched under lipotoxic stress and identified by proteomics.
- ZDHHC23‑mediated palmitoylation promotes NAT10 nuclear export and exosomal loading.
- Exosomal NAT10 increases ac4C-mediated stabilization of Ddr2 mRNA in HSCs, driving fibrogenesis.
- Hepatocyte‑specific Nat10 deletion or GalNAc‑siNat10 treatment reduced fibrosis in murine MASH; human liver NAT10 mislocalization correlated with fibrosis.
3. Integrated multi-omics and single-cell analyses identify metabolic heterogeneity and therapeutic vulnerabilities in medullary thyroid cancer.
Integrated bulk RNA‑seq, untargeted metabolomics, tissue IHC/multiplex IF, and single‑cell data define three metabolic subtypes of medullary thyroid cancer. A poor‑prognosis M3 subtype is characterized by upregulated glycosaminoglycan (GAG) biosynthesis—notably chondroitin sulfate—and CHSY1 overexpression, linked to EMT and tumor–stroma (myofibroblast) interactions. Two prognostic classifiers (8 metabolites; 28 metabolic genes) effectively stratify recurrence risk driven by GAG metabolism.
Impact: Defines a metabolically tractable poor‑prognosis subtype (CHSY1/GAG biosynthesis) and delivers validated prognostic classifiers that can inform precision management and nominate CHSY1 as a candidate therapeutic vulnerability in MTC.
Clinical Implications: Metabolic subtyping and CHSY1‑linked signatures may refine preoperative risk stratification and identify patients for targeted metabolic therapies or clinical trials; prospective validation and functional targeting of CHSY1 are next steps.
Key Findings
- Three metabolic subtypes identified in MTC; M3 subtype displays upregulated GAG biosynthesis and CHSY1 overexpression.
- M3 tumors show enhanced EMT signatures and tumor–stroma interactions implicating CHSY1.
- Prognostic models (8 metabolites; 28 genes) stratified recurrence risk with performance driven by GAG‑associated metabolism.